⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 3, 2026Metabolic Syndrome and Related Disorders

Joint Impact of Body Mass Index and High-Sensitivity C-Reactive Protein on Metabolic Dysfunction–Associated Steatotic Liver Disease Risk in Type 2 Diabetes

Chenyang Jiao Qian Xu Xiang Li J. Weng Kaiyue Lian Hai Liu

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to determine how BMI and hsCRP levels affect the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in individuals with type 2 diabetes.
Analyzed the association between BMI and hsCRP levels with MASLD incidence in type 2 diabetes.
Utilized statistical methods to assess risk stratification based on the elevation of both markers.
Elevated BMI and hsCRP were found to be independently linked to increased MASLD risk.
Co-elevation of BMI and hsCRP resulted in the highest risk of developing MASLD in type 2 diabetes.

Implication

Analysis shows that combining BMI and hsCRP improves risk assessment for liver disease in type 2 diabetes, suggesting targeted prevention approaches.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jiao et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd73a79560c99a0a38b9 https://doi.org/10.1177/15578518261438418

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Relationship between body mass index, liver enzymes and high-sensitivity C-reactive protein in type 2 diabetes mellitus patients2024
2Association of the C-reactive protein–triglyceride–glucose index with metabolic dysfunction-associated steatotic liver disease and long-term all-cause and cardiovascular mortality: evidence from two nationwide prospective cohort studiescohort · 2026 · 21 citations
3Adipocytokines as Predictors of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Development in Type 2 Diabetes Mellitus Patients2024 · 7 citations
4Association between serum meteorin-like protein and metabolic dysfunction–associated steatotic liver disease in patients with type 2 diabetes mellitus: a cross-sectional studyCross-Sectional Study · 2026 · 1 citations
5Determinants of Metabolic Dysfunction-Associated Steatotic Liver Diseases in Patients with Type 2 Diabetes Mellituscross-sectional · 2026

More related papers

Integrating lipometabolic and adiposity indices to enhance risk stratification for metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: clinical utility and interplay between triglyceride-glucose body mass index and low-density lipoprotein cholesterol2026
Atherogenic Combined Index is Independently Associated with MASLD in Type 2 Diabetes: A Cross-Sectional Study2025
Associations of the insulinemic potential of diet and lifestyle with metabolic dysfunction-associated steatotic liver disease (MASLD) risk in adults with type 2 diabetes2026

More from Metabolic Syndrome and Related Disorders

Real-World Implementation of Telemonitoring-Supported Care Redesign in Type 1 Diabetes: Reduced Outpatient Utilization with Preserved Glycemic OutcomesMon,
Cardiac Effects of Combined Versus Individual Interventions of Mediterranean Diet and Exercise in Adults with the Hypertriglyceridemic Waist Phenotype: A Randomized TrialMon,